ArticlePediatric cardiology2025
Chemical Cardioversion of Atrial Arrhythmias with Ibutilide in Children and Adults with Congenital Heart Disease.
Article in Pediatric cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a dearth of systematic data on efficacy and safety of ibutilide in children and adults with CHD and also in pediatric age-group patients. To determine the efficacy and safety of ibutilide in these populations, and to characterize the determinants of its efficacy. Patients with CHD and children < 18 years old with structurally normal hearts were recruited between Jan 1, 2010 and Dec 1, 2020. Logistic regression models were used to determine the effect of covariates on odds of successful cardioversion with ibutilide. 53 patients underwent 105 chemical cardioversions (age: 27.5 ± 10.4 years [75% males], 80% atrial flutter) with ibutilide during the study period. The overall rate of successful cardioversion with ibutilide in our cohort was 70.4% (mean ibutilide dose: 1.5 ± 0.65 mg). Presentation in atrial flutter (P = 0.08) and male gender (0.07) showed a trend towards significance. Adverse effects were reported after 8 ibutilide administrations (7.6%, n = 6/8 [75%] female).
Indexed as
Identifiers
39516379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.